Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 1/20 | 0.38 |
| ▸ | ATP4B | P51164 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31596156 | 1.00 | HTR2A (0.50) | HTR2ACALM1ALDH1A1HPGDBCL2 | |
| SCHEMBL8763318 | 0.86 | ALDH1A1 (0.50) | HTR2AALDH1A1HPGDCYP1A1CYP1A2 | |
| SCHEMBL10564000 | 0.84 | ALDH1A1 (0.46) | HTR2AALDH1A1HPGDFFAR1FFAR4 | |
| SCHEMBL10566854 | 0.84 | KEAP1 (0.58) | ALDH1A1HPGDBCL2BCL2L1CYP1A2 | |
| SCHEMBL10569734 | 0.84 | ALDH1A1 (0.40) | HTR2AALDH1A1HPGDCYP1A1CYP1A2 | |
| SCHEMBL9364439 | 0.84 | SLC6A4 (0.41) | HTR2AALDH1A1HPGDFFAR1FFAR4 | |
| SCHEMBL4863460 | 0.84 | ALDH1A1 (0.41) | HTR2AALDH1A1HPGDFFAR1FFAR4 | |
| SCHEMBL29809738 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1945874 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL7852993 | 0.82 | PAX8 (0.42) | CALM1BCL2BCL2L1ALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | GLAXO GROUP LIMITED | 2010-12-09 | — | — | US | disclosed |
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | GLAXO GROUP LIMITED | 2010-12-09 | — | — | US | disclosed |
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | GLAXO GROUP LIMITED | 2010-12-09 | — | — | US | disclosed |
| EP-2170807-A1 | SPIRO COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1 RECEPTOR | Glaxo Group Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016085-A1 | SPIRO COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016085-A1 | SPIRO COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| US-6703420-B1 | MITOGEN ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS; ANTIINFLAMMATORY, ANTICARCINOGENIC, OR ANTIPROLIFERATIVE AGENTS; RADIOSENSITIZERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-4070387-A | ANTIARRHYTHMIC AGENTS | MERCK & CO., INC. (US) | 1978-01-24 | — | — | US | disclosed |
| US-4020096-A | ANTIARRYTHMIA | MERCK & CO., INC. (US) | 1977-04-26 | — | — | US | disclosed |
| US-3950423-A | 10,11-Dihydro-10,10,11,11-tetrafluoro-5H-dibenzo[a,d]cycloheptene-5-methylamines | MERCK & CO., INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | HCRTR1, HCRTR2, HRH3 | HTR2A 137/4885CALM1 2548/4885ALDH1A1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.